The Regulatory Background In late 2023, the FDA placed 19 widely used peptides on its Category 2 restricted list, effectively barring compounding pharmacies from preparing them
doi:10.5009/gnl18490 Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B
Large-scale, randomized controlled trials are critically needed to establish definitive efficacy for specific clinical indications and to compare these peptides with established therapies
If you are looking for other ways to shape your body, The Beauty Lounge Toronto can help you explore your options
It is widely available through licensed pharmaceutical suppliers and is the diluent most commonly specified in UK trial protocols and compounding guidance from the Specialist Pharmacy Service (SPS)